Exicure, Inc.

Company Overview

Business Model: Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities, and halting of all research and development, initiating an exploration of strategic alternatives to maximize stockholder value. This effort involves exploring growth through acquisitions and transactions with potential partners, including in industries unrelated to its historical operations. As of January 19, 2025, Exicure, Inc. acquired GPCR Therapeutics USA Inc., a California corporation, which has an ongoing Phase 2 clinical trial focused on blood cancer patients.

Market Position: Historically, Exicure, Inc. operated in the competitive biotechnology sector. Following the sale of its historical biotechnology intellectual property and other assets in September 2024, the Company no longer owns any intellectual property in this field. Its current market position is in transition, focused on identifying new business opportunities through strategic transactions. The acquisition of GPCR Therapeutics USA Inc. marks a re-entry into the clinical-stage biopharmaceutical space, specifically targeting blood cancer therapeutics.

Recent Strategic Developments:

• Strategic Pivot: In September 2022, Exicure, Inc. suspended all research and development activities and began exploring strategic alternatives.
• Asset Divestiture: In February 2024, the Company received an upfront payment of $500,000 from a patent licensing agreement for cavrotolimod for potential hepatitis treatment. In the third quarter of 2024, it sold its historical biotechnology intellectual property and other assets, including this licensing agreement, for gross proceeds of $1,500,000.
• Change of Control & Financing: Effective November 12, 2024, HiTron Systems Inc. acquired 433,333 shares of common stock for $1.3 million. On December 24, 2024, HiTron Systems Inc. acquired an additional 2,900,000 shares for $8.7 million, resulting in HiTron Systems Inc. beneficially owning 53% of the outstanding common stock as of March 12, 2025.
• Acquisition: On January 19, 2025, Exicure, Inc. acquired all outstanding equity securities of GPCR Therapeutics USA Inc. from GPCR Therapeutics Inc. for $1.6 million. GPCR Therapeutics USA Inc. has an ongoing Phase 2 clinical trial for blood cancer patients.
• Nasdaq Compliance: As of December 17, 2024, the Company met all requirements for continued listing on The Nasdaq Capital Market, following multiple deficiency notices and reverse stock splits (one-for-thirty on June 29, 2022, and one-for-five on August 27, 2024). The Company is subject to a one-year mandatory panel monitor.
• Lease Termination: In February 2025, the Company terminated its Chicago, Illinois office lease, expecting to recognize a $6 million gain in the first quarter of 2025.

Geographic Footprint:

• The Company's corporate headquarters moved to Redwood City, California in January 2025, following the termination of its Chicago, Illinois lease.
• Future strategic efforts may be focused in Asia, leveraging relationships and business connections of its significant investors and board members, though domestic transactions will also be considered.
• The newly acquired GPCR Therapeutics USA Inc. is a California corporation, and its parent, GPCR Therapeutics Inc., is a Korean corporation.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: N/A
• Operating Margin: -2446.4%
• Net Margin: -1940.2%

Investment in Growth:

• R&D Expenditure: $0 million (0% of revenue)
• Capital Expenditures: Not explicitly disclosed, but net cash used in investing activities was $0 million in 2024.
• Strategic Investments:
  • Investment in convertible notes receivable of $2.0 million (May 2023), fully impaired in 2023.
  • Acquisition of GPCR Therapeutics USA Inc. for $1.6 million (subsequent event, January 2025).

Business Segment Analysis

Biotechnology

Financial Performance:

• Revenue: $0.5 million (+100% YoY)
• Operating Margin: -2446.4%
• Key Growth Drivers: The Company's 2024 revenue was solely derived from a patent license agreement for cavrotolimod for potential hepatitis treatment. Future growth is contingent on the successful identification and execution of strategic alternatives.

Product Portfolio:

• Historical: The Company's historical product portfolio, including spherical nucleic acid-related technology, research and development programs, and clinical assets, was sold in September 2024.
• Current (Post-Acquisition): The acquired GPCR Therapeutics USA Inc. has an ongoing Phase 2 clinical trial focused on blood cancer patients, involving the combined administration of G-CSF, GPC-100 (Burixafor), and propranolol.

Market Dynamics:

• The Company has exited its historical early-stage biotechnology development market. Its current strategy involves exploring new business lines and industries.
• With the acquisition of GPCR Therapeutics USA Inc., the Company has entered the blood cancer therapeutics market, characterized by high R&D costs and stringent regulatory pathways.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed.
• Dividend Payments: Exicure, Inc. has never declared or paid cash dividends and does not intend to for the foreseeable future.
• Dividend Yield: 0%
• Future Capital Return Commitments: None disclosed.

Balance Sheet Position:

• Cash and Equivalents: $12.5 million (as of December 31, 2024)
• Total Debt: $0 million (as of December 31, 2024, following debt to equity conversion)
• Net Cash Position: $12.5 million
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Promissory notes totaling $1.0 million were converted to equity in September 2024, resulting in no outstanding debt as of December 31, 2024.

Cash Flow Generation:

• Operating Cash Flow: $(2.9) million
• Free Cash Flow: Not explicitly stated, but negative given operating losses and minimal capital expenditures.
• Cash Conversion Metrics: Not explicitly disclosed.

Operational Excellence

Production & Service Model: Exicure, Inc. does not currently own or operate manufacturing facilities and, following its restructuring in September 2022, has no manufacturing or supply needs for its historical business. The Company's current focus is on exploring strategic alternatives, which may involve new operational models depending on future acquisitions. The newly acquired GPCR Therapeutics USA Inc. is engaged in clinical trial activities.

Supply Chain Architecture: Key Suppliers & Partners:

• Not applicable for current operations, as historical R&D and manufacturing activities have ceased.
• For GPCR Therapeutics USA Inc., specific details on its supply chain for clinical trial materials are not provided in the filing.

Facility Network:

• Corporate Headquarters: Moved to Redwood City, California in January 2025.
• Former Headquarters: The lease for approximately 30,000 square feet of office space in Chicago, Illinois, was terminated in February 2025.
• Research & Development: The Company no longer operates R&D centers for its historical business. GPCR Therapeutics USA Inc. has an ongoing Phase 2 clinical trial, indicating active clinical operations.
• Distribution: Not applicable for current operations.

Operational Metrics: Operational metrics are not explicitly disclosed for the Company's current transitional operations.

Market Access & Customer Relationships

Go-to-Market Strategy: Exicure, Inc. currently does not possess marketing, sales, and distribution capabilities for its historical business. Its strategy is focused on identifying and executing strategic transactions, which may lead to new go-to-market approaches depending on the nature of any acquired businesses. The acquired GPCR Therapeutics USA Inc. is in Phase 2 clinical trials, indicating a focus on clinical development rather than commercial sales and marketing.

Customer Portfolio:

• Enterprise Customers: Not applicable for the Company's current transitional state.
• Customer Concentration: Not applicable for the Company's current transitional state.

Geographic Revenue Distribution: The Company's 2024 revenue was derived from a single patent license agreement, with no specific geographic distribution disclosed.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The Company's historical industry (early-stage biotechnology) was characterized by intense competition and significant resource requirements for R&D, manufacturing, and regulatory approvals. The Company has pivoted from this industry and is now exploring growth through acquisitions across various sectors. The acquired GPCR Therapeutics USA Inc. operates in the blood cancer therapeutics market, which is typically characterized by high R&D investment, long development cycles, and stringent regulatory hurdles.

Competitive Positioning Matrix: Not applicable for the Company's current transitional state, as its historical intellectual property and assets have been sold.

Direct Competitors

Primary Competitors: Not applicable for the Company's current transitional state. Historically, competitors included large and small biotechnology companies, academic institutions, government agencies, and research institutions.

Emerging Competitive Threats: Not applicable for the Company's current transitional state.

Competitive Response Strategy: The Company's strategy is to explore growth through acquisitions and transactions with potential partners, rather than maintaining a competitive position in its historical biotechnology field.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Exploration of Strategic Alternatives: The Company's ability to execute its current business plan is dependent on obtaining additional funding via strategic transactions, which are complex, time-consuming, and may not deliver anticipated benefits.
• Uncertainty of Future Direction: Investor and potential business partner reactions to recent changes in control, board, and management composition, and the Company's future direction, could adversely impact its ability to obtain funding and execute strategic alternatives.
• Going Concern: Substantial doubt exists about the Company's ability to continue as a going concern due to limited liquidity and lack of current revenue, necessitating significant additional financing.
• Nasdaq Delisting: Risk of delisting from The Nasdaq Capital Market due to failure to meet listing standards (e.g., minimum bid price, stockholders' equity, corporate governance, timely filings). Although currently compliant, the Company is subject to a one-year mandatory panel monitor for the $2.5 million Equity Rule.
• Investment in Convertible Notes Receivable: The Company's $2.090 million investment in convertible notes receivable is unlikely to be redeemed, as the issuer appears to have ceased operations, potentially resulting in a complete loss of this investment.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Limited Resources: The Company operates with limited resources following prior reductions in force, which could impair its ability to comply with applicable laws, maintain adequate internal controls, and effectively manage risks, particularly when entering new business areas.
• Turnover of Management: Potential for additional turnover in the board and senior management creates significant continuity risks and challenges to business operations, risk assessment, and compliance. Attracting and retaining qualified personnel is expected to be challenging.

Financial & Regulatory Risks

Market & Financial Risks:

• History of Losses: The Company has incurred significant operating losses since its inception, with an accumulated deficit of $218.1 million as of December 31, 2024, and expects to continue incurring losses without product revenue in the foreseeable future.
• Dilution from Financing: Raising additional capital through equity offerings may materially dilute existing stockholders. Debt financing, if available, could involve restrictive covenants.
• Macroeconomic Conditions: Global macroeconomic conditions, including inflation, central bank actions, capital market instability, exchange rate fluctuations, supply chain disruptions, and energy/fuel prices, may adversely impact the Company's financial results and condition.

Regulatory & Compliance Risks:

• European Data Protection Laws: Due to prior clinical trial activities in the United Kingdom and Europe, the Company is subject to European data protection laws, including GDPR, with potential penalties for non-compliance and limitations on data utilization.
• Internal Control Over Financial Reporting: Management identified material weaknesses in internal control over financial reporting related to the review of non-routine activities and the design/implementation of controls around accounting and IT processes. This could impair the ability to produce accurate financial statements, leading to a loss of investor confidence or regulatory sanctions.
• Restatement of Financial Statements: Prior restatements of quarterly financial statements may affect stockholder and investor confidence, harm the Company's reputation, and lead to increased costs, legal proceedings, and regulatory inquiries.
• Section 16(a) Reports: Instances of late filings for Section 16(a) reports by officers and directors have occurred.

Geopolitical & External Risks

Geopolitical Exposure:

• Global Conflicts: The market price of the Company's common stock may be seriously harmed by broad market and industry factors, including those related to global conflicts (e.g., Russia’s invasion of Ukraine, Israel/Hamas war) and retaliatory actions.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas: Historically, the Company focused on its spherical nucleic acid (SNA) technology platform and nucleic acid therapies. All historical research and development activities were halted in September 2022. The acquired GPCR Therapeutics USA Inc. has an ongoing Phase 2 clinical trial for blood cancer, indicating a new R&D focus on its technologies. Innovation Pipeline: The Company no longer maintains an internal innovation pipeline for its historical biotechnology business. The innovation pipeline is now associated with the newly acquired GPCR Therapeutics USA Inc.

Intellectual Property Portfolio:

• Patent Strategy: Exicure, Inc. no longer owns any intellectual property, having sold its historical biotechnology intellectual property and other assets in September 2024.
• Licensing Programs: Any future value from historical IP is expected to be primarily through uncertain royalties and license fees from the purchase agreement.
• IP Litigation: Not applicable for the current IP portfolio, as it has been divested.

Technology Partnerships:

• Strategic Alliances: On January 19, 2025, Exicure, Inc. and GPCR Therapeutics Inc. entered into a License and Collaboration Agreement to further develop and commercialize GPCR's technologies related to certain intellectual property and patents.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The Company has experienced significant turnover in its board and senior management, creating continuity risks. The majority of current board members and management are directly affiliated with HiTron Systems Inc., the controlling stockholder. The Company anticipates significant competition in attracting and retaining experienced executives and other key personnel.

Board Composition: The Board of Directors consists of 7 directors: Andy Yoo, Seung Ik Baik, Ho Jung John, Chang Keun Choi, Minwoo Kang, Sangwook Song, and Dongho Lee. Andy Yoo, Seung Ik Baik, Ho Jung John, Chang Keun Choi, Minwoo Kang, and Sangwook Song were delegated to the Board by HiTron Systems Inc. The Audit Committee is comprised of Minwoo Kang (Chairperson), Chang Keun Choi, and Dongho Lee, all determined to be independent. Mr. Kang qualifies as an "audit committee financial expert." Following the stock purchase agreement with HiTron Systems Inc. in December 2024, Exicure, Inc. again became a "controlled company" under Nasdaq rules.

Human Capital Strategy

Workforce Composition:

• Total Employees: 7 full-time employees as of December 31, 2024.
• Geographic Distribution: Not explicitly detailed, but corporate headquarters are in Redwood City, California.
• Skill Mix: Employees are primarily engaged in finance and general management activities, following the wind-down of research and development programs.

Talent Management: Acquisition & Retention: The Company expects to face significant competition in attracting experienced executives and other key personnel, particularly given its controlled status, transitional state of operations, and financial condition. Diversity & Development: Not explicitly detailed in the filing. Culture & Engagement: Not explicitly detailed in the filing.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations: Historically, the Company's therapeutic candidates were subject to extensive regulation by governmental authorities (e.g., U.S. Food and Drug Administration) in the U.S. and other countries. Any third parties licensing or acquiring its assets would need to comply with such regulations. International Compliance: By virtue of prior clinical trial activities in the United Kingdom and Europe, the Company is subject to European data protection laws, including the European Union’s General Data Protection Regulation 2016/679 (GDPR).

Trade & Export Controls: Not explicitly detailed in the filing.

Legal Proceedings:

• Securities Class Action: A putative securities class action lawsuit (Colwell v. Exicure, Inc. et al.) was settled, with final judgment entered on January 13, 2025. The settlement is fully covered by insurance, but the Company recorded an accrual of approximately $1.14 million for the unsatisfied portion of its self-insured retainer.
• Shareholder Derivative Lawsuits: Three separate shareholder derivative lawsuits (Puri v. Giljohann, et al.; Sim v. Giljohann, et al.; Stourbridge Investments LLC v. Exicure, Inc. et al.) are currently stayed, with the Company engaged in settlement discussions.
• Former Employee Complaint: A complaint filed by a former employee in October 2023 is in the discovery phase, with parties working through alleged discovery deficiencies.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: (0.1)% for the year ended December 31, 2024, and 0% for the year ended December 31, 2023.
• Geographic Tax Planning: Not explicitly detailed.
• Tax Reform Impact: The Company is subject to IRC Section 174 regulations, requiring capitalization of certain research and experimental expenditures, and IRC Section 382 loss limitation rules.
• Net Operating Losses (NOLs): As of December 31, 2024, the Company had a federal net operating loss carryforward of $13.951 million (indefinitely lived) and state net operating loss carryforwards of $13.951 million (expiring starting 2044).
• Ownership Change Impact: The Company experienced an "ownership change" in the fourth quarter of 2022 and another in December 2024. As of December 31, 2023, the Company "discontinued the original business," which subjects its pre-change NOL carryforwards to a zero limitation under Section 382(c), fully restricting their use to offset taxable income.
• Valuation Allowance: A full valuation allowance has been established against deferred tax assets due to significant cumulative losses and projected future taxable losses.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: The Company maintains insurance coverage at levels it believes are appropriate for its business. The settlement of the securities class action lawsuit was fully covered by insurance, with the Company accruing $1.14 million for its self-insured retainer.
• Risk Transfer Mechanisms: Not explicitly detailed beyond insurance coverage.